The pipeline of antibiotic discovery is a major necessity due to the continuous evolution of resistance to currently used antimicrobials. This pipeline faces important challenges due to the lack of investment on antimicrobial research in the private sector and an economic model that discourages investment. In the last few years, however, encouraging signs are occurring but major gaps still remain. The World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline and the latest report is now available in the journal, lets discuss it!
Topics discussed:
- The process for review of the antibacterial pipeline.
- The progress and gaps in antibiotic discovery
- The opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space
Guest:
- Valeria Gigante Ph.D., Team Lead at the World Health Organization's (WHO) in the AMR Division, Geneva, Switzerland.
Link:
This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at . If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up.
Visit to browse issues and/or submit a manuscript.
Subscribe to Editors in Conversation (free) on , , .